Filtered By:
Management: Marketing
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 200 results found since Jan 2013.
FDA Permits Marketing of Clinical Decision Support Software for Alerting Providers of a Potential Stroke in Patients
Today, the U.S. Food and Drug Administration permitted marketing of the Viz.AI Contact application, a type of clinical decision support software designed to analyze computed tomography (CT) results that may notify providers of a potential stroke in their patients.
Source: eHealth News EU - February 13, 2018 Category: Information Technology Tags: Featured Industry Business and Industry Source Type: news
FDA permits marketing of clinical decision support software for alerting providers of a potential stroke in patients
Source: Food and Drug Administration - February 13, 2018 Category: American Health Source Type: news
Zynex introduces the NeuroMove(TM) Device to its expanding sales force
LONE TREE, Colo., Feb. 1, 2018 -- (Healthcare Sales & Marketing Network) -- Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilita... Devices, Product Launch Zynex, electrotherapy, NeuroMove
Source: HSMN NewsFeed - February 1, 2018 Category: Pharmaceuticals Source Type: news
New Study Shows Superiority of Intrathecal Baclofen Therapy (ITB Therapy(SM)) Over Oral Medication for the Treatment of Severe Post-Stroke Spasticity
Therapy Delivered via the Medtronic SynchroMed(TM) II Infusion System
DUBLIN - January 11, 2018 -- (Healthcare Sales & Marketing Network) -- Medtronic plc (NYSE:MDT) today announced the publication of results from the 'Spasticity In Stroke-Randomised St... Devices, Drug Delivery, Neurology Medtronic, Intrathecal Baclofen Therapy, baclofen, SynchroMed, Stroke
Source: HSMN NewsFeed - January 11, 2018 Category: Pharmaceuticals Source Type: news
First Patient Enrolled in U.S. IDE Study To Evaluate the Potential of New Device To Reduce Stroke Risk in Atrial Fibrillation Patients
Biosense Webster, Inc. Launches U.S. Clinical Study to Evaluate the Safety and Efficacy of the WaveCrest® Left Atrial Appendage Occlusion System
IRVINE, Calif., Jan. 11, 2018 -- (Healthcare Sales & Marketing Network) -- Johnson & Johnson Medical De... Devices, Interventional Cardiology Biosense Webster, Johnson & Johnson, WaveCrest, Left Atrial Appendage Occlusion
Source: HSMN NewsFeed - January 11, 2018 Category: Pharmaceuticals Source Type: news
ESO Solutions Predicts Key Hospital Trends to Watch in 2018
Austin, Texas – ESO Solutions, the leading data and software company serving emergency medical services, fire departments, and hospitals, today shared the trends it predicts will have the biggest impact on hospitals in 2018: A greater emphasis on evidence-based approaches to acute conditions; healthcare financing changes affecting the way hospitals admit and readmit patients; reshuffling of hospital ownership; and a shift in how patient volume is managed.
“Few areas of healthcare have seen more significant change over the past several years than hospitals,” said Allen Johnson, Vice President of ESO HDE and Analytics....
Source: JEMS: Journal of Emergency Medical Services News - January 5, 2018 Category: Emergency Medicine Authors: ESO Solutions Tags: Patient Care Industry News Source Type: news
11.12.17: Not intended for U.S. and UK Media
Bayer's rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery diseaseThe rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack / The application for marketing approval is based on the COMPASS studymehr ...
Source: Bayer IR Newsfeed: Events - December 10, 2017 Category: Pharmaceuticals Source Type: news
Stroke Rehab Technology Aims To Speed Healing
Watching someone who has suffered a stroke try to perform everyday actions such as walking down the sidewalk or even bringing a cup to their lips can serve as a sobering reminder of how fragile full and robust health is, and also serves as an inspiration for those dedicated to improving the lives of those patients.
Steven Plymale, recently named CEO of Toronto-based MyndTec, said his reaction to watching videos of patients using the company's MyndMove functional electrical stimulation (FES) rehabilitation system was one of the reasons he joined MyndTec.
"They are very compelling," Plymale said of the demonstration videos,...
Source: MDDI - November 22, 2017 Category: Medical Devices Authors: Greg Goth Tags: Electronics Source Type: news
Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency (for specialized target groups only)
The rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack / The application for marketing approval is based on the COMPASS study / If approved, the rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin low dose once daily, will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated for this patient population
Source: Bayer Company News - November 6, 2017 Category: Pharmaceuticals Source Type: news
06.11.17: Not intended for U.S. and UK Media
Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines AgencyThe rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack (1) / The application for marketing approval is based on the COMPASS study / If approved, the rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin low dose once daily, will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated for this patient populationmehr ...
Source: Bayer IR Newsfeed: Events - November 5, 2017 Category: Pharmaceuticals Source Type: news
Silk Road Medical Appoints World Class Stroke Prevention Champion to Serve as Vice President, Medical Affairs and Professional Education
Tammy Leitsinger to spearhead global physician education and peer-to-peer training for rapidly growing Trans Carotid Artery Revascularization (TCAR) procedure
SUNNYVALE, Calif., Oct. 11, 2017 -- (Healthcare Sales & Marketing Network) -- Silk Road Medic... Devices, Neurology, Personnel Silk Road Medical, ENROUTE, TransCarotid Artery Revascularization, stroke
Source: HSMN NewsFeed - October 11, 2017 Category: Pharmaceuticals Source Type: news
Cheetah Medical raises $12m
Cheetah Medical said today it raised $11.8 million in an expanded Series C funding round as it looks to grow its US footprint.
Financing was provided by existing investors including MVM Life Science Partners, Springfield Investment Management, Fletcher Spaght Ventures, HighCape Partners and Robert Basch Venture Capital, the Newton, Mass.-based company said.
Cheetah Medical provides noninvasive hemodynamic monitoring devices and systems, including its Cheetah Nicom and Starlin SV technologies, which operate around a proprietary algorithm designed to allow physicians to examine a patient’s full hemodynamic profile.
&#...
Source: Mass Device - September 14, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cheetah Medical Source Type: news
IRRAS Strengthens Executive and Commercial Teams with Appointments of Karl-Matthias Moehlmann and Klemens Fölling
LA JOLLA, Calif., LAICHINGEN, Germany and STOCKHOLM, Sept. 13, 2017 -- (Healthcare Sales & Marketing Network) -- IRRAS, a commercial-stage medical technology company developing breakthrough devices for a broad range of intracranial bleeding applications a... Devices, Neurology, Personnel IRRAS, IRRAflow, stroke, intracranial pressure
Source: HSMN NewsFeed - September 13, 2017 Category: Pharmaceuticals Source Type: news
